56
Growth Score
pts
Heat Score
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
766814
This company is develops small-molecule drugs that ameliorate mitochondrial disease.
About the Company
Ixchel focuses on developing drugs that cure mitochondrial diseases for which there are currently no FDA-approved treatments. The majority of mitochondrial diseases are considered orphan and affect less than 200,000 people in the US. Ixchel has utilized a repurposing approach to isolate drugs for a number of debilitating orphan mitochondrial
diseases including Friedreich’s ataxia (FA), Mitochondrial Myopathy (MM), and Leber’s hereditary optic neuropathy (LHON).
